Physician profile
Weining Liang
NPI 1033222831
$132,644.83
in general payments reported to CMS, 2019-2025
45 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $6,310 · 2021: $16K · 2022: $21K · 2023: $13K · 2024: $20K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $6,919 · Travel and Lodging: $488 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,115.00 |
| Food and Beverage | $6,918.65 |
| Travel and Lodging | $488.09 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $78,735.34 | 2019-2025 | Vemlidy |
| Abbvie INC. | $35,915.54 | 2019-2025 | |
| Insmed, INC. | $9,032.08 | 2019-2025 | Arikayce |
| Amarin Pharma, INC. | $1,190.67 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $911.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $902.61 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $845.04 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $640.02 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $529.09 | 2019-2023 | Belsomra |
| Pfizer INC. | $483.63 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $451.09 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $396.46 | 2019-2023 | Mitigare, Ryaltris |
| Ibsa Pharma INC. | $333.74 | 2021-2025 | Tirosint, Licart, Licart |
| Novartis Pharmaceuticals Corporation | $167.60 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $166.97 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weining Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.